ILK and neoplasm: It is assumed that BMDCs can promote a proglycolytic phenotype in tumor cells, thus giving them a survival advantage in hypoxic and inflammatory conditions [9], or promote tumor cell survival through the activation of the integrin-linked kinase (ILK), thereby activating the prosurvival AKT signaling pathway [10].